

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1-45. (Canceled).

46. (Currently amended) A method for promoting neurite outgrowth or promoting neuronal protection against neuronal damage ~~reducing spatial or declarative memory dysfunction caused by damaged hippocampal tissue~~ in a mammal exhibiting spatial or declarative memory dysfunction, comprising the steps of: determining the existence of spatial or declarative memory dysfunction, and administering OP-1 to the mammal; wherein the spatial or declarative memory dysfunction is caused ~~damaged hippocampal tissue is damaged~~ by ibotenic acid, ammonia and formaldehyde; and wherein OP-1 promotes neurite outgrowth or promotes neuronal protection against neuronal damage.

47. (Canceled).

48. (Currently amended) A method for promoting neurite outgrowth or promoting neuronal protection against neuronal damage ~~reducing spatial or declarative memory dysfunction caused by damaged hippocampal tissue~~ in a mammal exhibiting spatial or declarative memory dysfunction, comprising the steps of: determining the existence of spatial or declarative memory dysfunction, and administering OP-1 to the mammal; wherein the spatial or declarative memory dysfunction is caused ~~damaged hippocampal tissue is damaged~~ by malnutrition, glucose metabolism disorder, or anorexia; and wherein OP-1 promotes neurite outgrowth or promotes neuronal

protection against neuronal damage.

49-50. (Canceled) .

51. **(Previously presented)** The method of claim 48, wherein the mammal is afflicted with malnutrition.
52. **(Previously presented)** The method of claim 48, wherein the mammal is afflicted with a glucose metabolism disorder.
53. **(Previously presented)** The method of claim 48, wherein the mammal is afflicted with anorexia.
54. **(Previously presented)** The method of claim 46 or 48, wherein said OP-1 comprises residues 30-292 of SEQ ID NO:2.
55. **(Previously presented)** The method of claim 46 or 48, wherein said OP-1 comprises residues 330-431 of SEQ ID NO:2.
56. **(Previously presented)** The method of claim 46 or 48, wherein said OP-1 comprises residues 48-292 of SEQ ID NO:2.
57. **(Previously presented)** The method of claim 46 or 48, wherein said OP-1 comprises the amino acid sequence of SEQ ID NO:2.
58. **(Previously presented)** The method of claim 46 or 48, wherein said OP-1 comprises a mature form of human OP-1, defined by residues 293-431 of SEQ ID NO: 2.
59. **(Previously presented)** The method of claim 46 or 48, wherein the OP-1 is administered by intraventricular administration.
60. **(Previously presented)** The method of claim 46 or 48, wherein the OP-1 is disposed in a biocompatible microsphere.